Jupiter Neurosciences, Inc. JUNS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -55.91% | -175.25% | -254.36% | -466.30% | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 63.78% | 171.90% | 682.94% | 3,181.00% | -- |
| Total Other Non-Cash Items | -11.43% | 141.05% | 136.57% | 5,013.48% | -- |
| Change in Net Operating Assets | 67.12% | 102.11% | 104.18% | -384.01% | -- |
| Cash from Operations | -28.77% | -17.80% | -38.42% | -1,691.05% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 18,815.25% | 5,867.91% | 3,928.88% | -99.44% | -- |
| Total Debt Repaid | 76.61% | 93.80% | 93.80% | -- | -- |
| Issuance of Common Stock | 1,765.50% | -96.33% | -- | 100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -8.01% | -28.50% | -28.99% | 2,254.89% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -119.13% | -112.74% | -99.47% | 1,318.18% | -- |